Cargando…
Bedaquiline inhibits the yeast and human mitochondrial ATP synthases
Bedaquiline (BDQ, Sirturo) has been approved to treat multidrug resistant forms of Mycobacterium tuberculosis. Prior studies suggested that BDQ was a selective inhibitor of the ATP synthase from M. tuberculosis. However, Sirturo treatment leads to an increased risk of cardiac arrhythmias and death,...
Autores principales: | Luo, Min, Zhou, Wenchang, Patel, Hiral, Srivastava, Anurag P., Symersky, Jindrich, Bonar, Michał M., Faraldo-Gómez, José D., Liao, Maofu, Mueller, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438494/ https://www.ncbi.nlm.nih.gov/pubmed/32814813 http://dx.doi.org/10.1038/s42003-020-01173-z |
Ejemplares similares
-
Structure of the c(10) Ring of the Yeast Mitochondrial ATP Synthase in the Open Conformation
por: Symersky, Jindrich, et al.
Publicado: (2012) -
Atomistic simulations indicate the c-subunit ring of the F(1)F(o) ATP synthase is not the mitochondrial permeability transition pore
por: Zhou, Wenchang, et al.
Publicado: (2017) -
Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase
por: Kundu, Subhashri, et al.
Publicado: (2016) -
Mitochondrial ATP synthase dimers spontaneously associate due to a long-range membrane-induced force
por: Anselmi, Claudio, et al.
Publicado: (2018) -
Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)